作者：
Tsunashima,D. [1]
;
Kawamura,A. [2]
;
Murakami,M. [3]
;
Sawamoto,T. [4]
;
Undre,N. [5]
;
Brown,M. [6]
;
Groenewoud,A. [7]
;
Keirns,J.J. [8]
;
Holman,J. [9]
;
Connor,A. [10]
;
Wylde,H. [11]
;
Wilding,I. [12]
;
Ogawara,K.-I. ;
Sako,K. ;
Higaki,K. ;
First,R.
作者单位：
Global Medical Affairs, Astellas Pharma, Northbrook, IL, United States
[1]
Clinical Pharmacology, Astellas Pharma Inc, Tokyo, Japan
[2]
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, Okayama, Japan
[3]
Pharmaceutical Research and Technology Laboratories, Astellas Pharma Inc, Shizuoka, Japan
[4]
IM/IDI Transplant, Astellas Pharma Global Development Inc, Northbrook, IL, United States
[5]
Clinical Pharmacology, Astellas Pharma Global Development Inc, Northbrook, IL, United States
[6]
Quotient Clinical, Ruddington, Nottinghamshire, United Kingdom
[7]
Medical Sciences, Astellas Pharma Global Development Inc, Northbrook, IL, United States
[8]
Medical Affairs Europe, Astellas Pharma Europe Ltd, Chertsey, Surrey, United Kingdom
[9]
Astellas Pharma Europe Ltd, Chertsey, Surrey, United Kingdom
[10]
Project Management, Astellas Pharma Inc, Tokyo, Japan
[11]
Drug Metabolism Research Laboratories, Astellas Pharma Inc, Osaka, Japan
[12]
发布时间
2014-07-16
换一批
